TC
ABBV icon

Tsai Capital’s AbbVie ABBV Stock Holding History

Tsai Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,800
Closed -$243K – 24
2023
Q2 		$243K Hold
1,800
– – 0.22% 23
2023
Q1 		$287K Sell
1,800
-300
-14% -$45.9K 0.3% 23
2022
Q4 		$339K Sell
2,100
-300
-13% -$46K 0.49% 21
2022
Q3 		$322K Hold
2,400
– – 0.36% 21
2022
Q2 		$368K Hold
2,400
– – 0.44% 19
2022
Q1 		$389K Sell
2,400
-1,600
-40% -$232K 0.3% 15
2021
Q4 		$542K Hold
4,000
– – 0.38% 14
2021
Q3 		$431K Sell
4,000
-400
-9% -$45.7K 0.37% 15
2021
Q2 		$496K Hold
4,400
– – 0.46% 16
2021
Q1 		$476K Hold
4,400
– – 0.47% 17
2020
Q4 		$471K Buy
+4,400
New +$423K 0.47% 15

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tsai Capital's ABBV Position: Q3 2023 in Review

Tsai Capital sold out of AbbVie (ABBV) in Q3 2023, closing a stake of 1,800 shares — an estimated $243K sold.

Tsai Capital first reported a position in ABBV in Q4 2020 and held it in 11 quarters. The position peaked at $542K in Q4 2021. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

  • Tsai Capital reported no remaining AbbVie position as of Q3 2023 after selling out during the quarter.
  • Tsai Capital sold 1,800 AbbVie shares in Q3 2023, an estimated $243K.
  • Tsai Capital first reported a position in AbbVie in Q4 2020 and held it in 11 quarters.
  • Tsai Capital's AbbVie position peaked at $542K in Q4 2021.
  • 3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Tsai Capital's 13F filing for Q3 2023, filed 14 Nov 2023.